You are in: eMedicine Specialties >
Gastroenterology > Esophagus
Esophagitis
Article Last Updated: Jul 17, 2008
AUTHOR AND EDITOR INFORMATION
Section 1 of 11  
Author: Sajid Ansari, MD, Consulting Staff, Department of Gastroenterology, St Anthony's Medical Center
Sajid Ansari is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, and Missouri State Medical Association
Coauthor(s):
Sandeep Mukherjee, MB, BCh, MPH, FRCPC, Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center
Editors: Maurice A Cerulli, MD, FACG, Chief, Division of Gastroenterology and Hepatology, Associate Professor of Clinical Medicine, Department of Internal Medicine, Division of Gastroenterology, New York Methodist Hospital, Cornell University; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Simmy Bank, MD, Chair, Professor, Department of Internal Medicine, Division of Gastroenterology, Long Island Jewish Hospital, Albert Einstein College of Medicine; Alex J Mechaber, MD, FACP, Assistant Dean for Medical Curriculum, Associate Professor of Medicine, Division of General Internal Medicine, University of Miami Miller School of Medicine; Julian Katz, MD, Clinical Professor of Medicine, Drexel University College of Medicine; Consulting Staff, Department of Medicine, Section of Gastroenterology and Hepatology, Hospital of the Medical College of Pennsylvania
Author and Editor Disclosure
Synonyms and related keywords:
gastritis, peptic ulcer disease, PUD, gastroesophageal reflux disease, GERD, hiatal hernia, fungal esophagitis, Candida esophagitis, herpes simplex virus esophagitis, HSV esophagitis, cytomegalovirus esophagitis, CMV esophagitis, varicella-zoster virus esophagitis, VZV esophagitis, Epstein-Barr virus esophagitis, EBV esophagitis, HIV esophagitis, human papillomavirus esophagitis, HPV esophagitis, Mycobacterium tuberculosis esophagitis, drug-induced esophagitis, medication related-esophagitis, graft versus host disease esophagitis, eosinophilic esophagitis, infective esophagitis, infectious esophagitis, achalasia, progressive systemic sclerosis, esophageal neoplasias, steroid therapy, immunosuppressive medications, pill esophagitis, dysphagia, odynophagia, epidermolysis bullosa, Stevens-Johnson syndrome, toxic epidermal necrolysis, cicatricial pemphigoid, lichen planus, psoriasis, acanthosis nigricans, leukoplakia, pemphigus vulgaris, erythema multiforme, bullous pemphigoid, collagen vascular disease, metastatic cancer, chronic granulomatous disease, sarcoidosis, inflammatory bowel disease
Background
The most common cause of esophagitis is Gastroesophageal Reflux Disease (GERD). Other important, but less common, causes are infections, medications, radiation therapy, systemic disease, and trauma. Eosinophilic esophagitis has emerged as an important cause of esophagitis in both children and adults. This article does not discuss GERD-induced esophagitis.
Pathophysiology
The pathophysiology of esophagitis depends on its etiology. Infective esophagitis is most commonly observed in immunosuppressed hosts but has also been reported in healthy adults and children. A wide range of abnormalities in host defense may predispose an individual to opportunistic infections, such as neutropenia, impaired chemotaxis and phagocytosis, alteration in humoral immunity, and impaired T-cell lymphocyte function. Steroids, cytotoxic agents, radiation, and immune modulators can also contribute to impaired host immune function. Disruption of mucosal protective barriers and antibiotics that suppress the normal bacterial flora may contribute to the invasive ability of commensal organisms. The prevalence of symptomatic infection is high in individuals with AIDS, leukemia, and lymphoma and is low (<5%) in the general medical population. In people with HIV, the most significant risk factor is a persistently low CD4 count, but reports exist of individuals who develop fungal esophagitis during the seroconversion phase. Patients with systemic diseases (eg, diabetes mellitus, adrenal dysfunction, alcoholism) and those of advanced age can be predisposed to infectious esophagitis because of altered immune function. Illnesses that interfere with esophageal peristalsis, such as achalasia, progressive systemic sclerosis, and esophageal neoplasias, may contribute to fungal esophagitis. Steroid therapy and other immunosuppressive medications contribute to fungal infection by suppressing both lymphocyte function and granulocyte function. Other medications associated with pill esophagitis cause injury by local or topical injury. Other medications, usually medications associated with pill esophagitis, cause injury by local contact. The mechanism of eosinophilic esophagitis remains to be elucidated. However, a corrugated esophagus characterized by fine concentric mucosal rings is commonly observed in patients and believed to be related to histamine released from sensitized mast cells in the esophageal wall. This activates a cascade of reactions culminating in acetylcholine release that contracts muscle fibers in the muscularis mucosae resulting in the formation of concentric esophageal rings. This hypothesis can be tested by performing endoscopic ultrasound, which will reveal contraction of the muscle layers of the muscularis mucosae and may be related to immunoglobulin E (IgE) activation.
Frequency
United States
Unknown
International
Unknown
Mortality/Morbidity
Patients may experience dysphagia, pain, odynophagia, and malnutrition in severe esophagitis. Rarely, life-threatening bleeding occurs and may lead to death. Outcomes and survival in these patients are related to the severity of their underlying systemic illness.
Race
No racial predilection is observed.
Sex
No sexual predilection is observed.
Age
No age-related differences are reported. Esophagitis is commonly seen in adults and is uncommon in childhood.
History
A history of immunosuppression, steroid therapy, recent antibiotic use, or systemic illness supports the diagnosis. Although patients may be asymptomatic, typical symptoms include the following: - Onset of difficult or painful swallowing (ie, dysphagia, odynophagia)
- Heartburn
- Retrosternal discomfort or pain
- Nausea, vomiting
- Fever, sepsis
- Abdominal pain
- Epigastric pain
- Hematemesis (occasionally)
- Anorexia, weight loss (depends on chronicity and severity of underlying illness)
- Cough
Physical
- Look for signs of immunosuppression and skin signs of systemic disease (eg, telangiectasias and sclerodactyly in scleroderma).
- Examine the oral cavity (for thrush or ulcers).
Causes
See Histologic Findings.
- Infectious causes include the following:
- Candida species
- Noncandidal fungi (eg, Aspergillus, Histoplasma, Cryptococcus, Blastomyces)
- Herpes simplex virus (HSV)
- Cytomegalovirus (CMV)
- Varicella-zoster virus (VZV)
- Epstein-Barr virus (EBV)
- In HIV-infected hosts - CMV, HSV, Mycobacterium avium-intracellulare, idiopathic
- Human papillomavirus (HPV)
- Poliovirus
- Bacterial species (eg, normal flora, Mycobacterium tuberculosis, Mycobacterium avium-intracellulare)
- Parasitic infections (eg, Chagas disease, Trypanosoma cruzi, Cryptosporidium, Pneumocystis, Leishmania donovani)
- Systemic illnesses include the following:
- Skin disorders
- Epidermolysis bullosa
- Pemphigus vulgaris
- Bullous pemphigoid
- Cicatricial pemphigoid
- Drug-induced skin disorders (eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Other skin disorders (eg, lichen planus, psoriasis, acanthosis nigricans, leukoplakia)
- Eosinophilic esophagitis
- Behçet disease
- Graft versus host disease (GVHD)
- Inflammatory bowel disease (Crohn disease)
- Sarcoidosis
- Chronic granulomatous disease
- Metastatic cancer
- Collagen vascular disease
- Medications
- Pill esophagitis (eg, Fosamax)
- Antibiotics (eg, tetracycline)
- Potassium
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Quinidine
- Chemotherapy (eg, dactinomycin, bleomycin, cytarabine, daunorubicin, 5-fluorouracil, methotrexate, vincristine)
- Radiation therapy
Angina Pectoris
Gastroesophageal Reflux Disease
Peptic Ulcer Disease
Pulmonary Embolism
Other Problems to be Considered
Coronary artery disease
Pericarditis
Aortic aneurysm
Nonulcer reflux disease
Functional dyspepsia
Stricture
Lab Studies
- CBC count in patients with neutropenia or who are immunosuppressed
- CD4 count and HIV test in patients with risk factors for HIV
Imaging Studies
- Barium studies are recommended as the initial imaging study in patients presenting with dysphagia.
- A case can be made for initial upper endoscopy because this approach would reveal more diagnostic information (eg, inflammatory characteristics, ability to obtain samples for pathological examination, cytological examination, viral and bacterial cultures). Barium studies are less accurate for mucosal detail and can also reduce the capability of obtaining positive cultures.
- The authors do not recommend barium studies for patients with absolute dysphagia or odynophagia. Upper endoscopy would be recommended under these circumstances. The authors view barium studies and upper endoscopy as complementary rather than competing tests in the evaluation of patients with dysphagia.
Other Tests
- No specific other tests are recommended; other tests are performed based on underlying disease (eg, CD4 count in HIV, CBC count in neutropenia) and collagen workup (eg, antinuclear antibody [ANA], anti-dsDNA).
Procedures
- Esophagogastroduodenoscopy (EGD) is preferred in patients with odynophagia because this is a specific symptom of esophagitis. EGD is the main diagnostic tool used for esophagitis.
- Allows mucosal visualization
- Can obtain mucosal biopsies and brushings
- Wide variety of findings based on the underlying cause
- Blind brush cytology has been used in the past; however, with the availability of EGD, its use has diminished. It is performed by passing a cytology brush in a sheath similar to a nasogastric or orogastric tube. Once the end of the catheter is in the mid esophagus, the brush is extended and brushings are taken. Finally, the brush is withdrawn back into the sheath. This is performed without any direct visualization, as occurs when brushings are performed during an EGD.
Histologic Findings
Candida Oral thrush is a frequent finding and is often an indicator of esophageal involvement. Oral thrush can be absent in 25% of cases of Candida esophagitis. Candida infection is frequently asymptomatic. The grading scale for candidal esophagitis is as follows:
- Grade 1 - Few raised white plaques up to 2 mm in size, no ulceration
- Grade 2 - Multiple raised white plaques more than 2 mm in size, no ulceration
- Grade 3 - Confluent, linear, nodular, elevated plaques with ulceration
- Grade 4 - Grade 3 with narrowed lumen
Candida plaques are typically creamy white or pale yellow, with underlying raw mucosa. Brushings should be obtained with a sheathed cytology brush, spread onto slides, and stained with periodic acid-Schiff, silver, or Gram stains. The presence of mycelial forms and masses of budding yeast is consistent with candidal infection. Cultures are seldom indicated because Candida species are commensal organisms, and differentiating normal flora from infection is difficult. Cultures are useful for resistant Candida or Aspergillus. Herpes simplex virus HSV esophagitis diagnosis is made at endoscopy. The earliest esophageal lesions are rounded 1- to 3-mm vesicles in the middle to distal esophagus. Centers slough to form discrete circumscribed ulcers with raised edges. Advanced HSV esophagitis may be indistinguishable from candidal esophagitis. Plaques, cobblestoning, or a shaggy ulcerative appearance is observed. HSV preferentially infects epithelial cells. Biopsy should be performed on ulcer margins of islands of squamous mucosa for histology and culture (see Media file 1). The ulcer base is devoid of epithelial cells and is inadequate to diagnose HSV esophagitis. Immunologic staining of centrifugation cultures is more sensitive than routine histology.
- Multinucleated giant cells
- Ballooning degeneration
- Ground glass intranuclear Cowdry type A inclusion bodies
- Margination of chromatin
Immunohistologic stains using monoclonal antibodies to HSV antigens or in situ hybridization techniques may improve the yield in difficult cases. Cytomegalovirus See Cytomegalovirus Esophagitis. The virus infects submucosal fibroblasts and endothelial cells, not the squamous epithelium (see Media file 1). Diagnosis depends on biopsies from the EGD. Superficial erosions with serpiginous nonraised borders in the middle to distal esophagus are observed. With infection progression, shallow ulcerations may deepen and expand for 5-10 cm. Tissue is needed for confirmation; obtain multiple biopsies from the ulcer base. Varicella-zoster virus This organism can cause severe esophagitis. The key to diagnosis is finding concurrent dermatologic VZV lesions. The appearance on EGD ranges from occasional vesicles to discrete ulcerative lesions to a confluence of ulcerations with necrosis. On histologic examination, epithelial cells with VZV show edema, ballooning degeneration, and multinucleated giant cells with intranuclear eosinophilic inclusion bodies. Immunohistochemical staining using monoclonal antibodies is helpful to differentiate VZV from HSV. Epstein-Barr virus Histologic features of esophageal lesions are similar to those of oral hairy leukoplakia. Human immunodeficiency virus Multiple, small, aphthoid lesions are observed during the period of transient fever, chills, malaise, and rash of early HIV infection. Later, giant deep ulcers extending up several centimeters are observed. Fistula formation, perforation, hemorrhage, or superinfection may complicate large ulcers. Human papillomavirus HPV esophagitis is asymptomatic. Lesions are typically found in the middle to distal esophagus. They may appear as erythematous macules, white plaques, nodules, or exuberant frondlike lesions. The diagnosis is made based on histology. Koilocytosis, giant cells, and cytologic atypia are visible on immunohistochemical stains. Mycobacterium tuberculosis Esophageal symptoms result from direct extension from adjacent mediastinal structures. EGD reveals shallow ulcers, heaped-up lesions mimicking neoplasia, and extrinsic compression of the esophagus. Specimens should be sent for acid-fast stains and mycobacterial culture. Drug-induced skin disease Drug-induced skin diseases, which rarely occur, affect the esophagus with a blistering process and desquamation of large areas of epithelium. Both focal and long strictures and webs may form. Behçet disease Esophageal involvement is rare. Esophageal lesions include ulcerations that can tunnel the mucosa, strictures, fistulous tracts, and perforations. Graft versus host disease Histologic changes in acute GVHD are observed in the squamous epithelium, including the esophagus. Chronic GVHD damages the esophagus more extensively. Generalized desquamation is visible on EGD. Barium contrast radiographs may reveal webs, rings, and tight strictures in the upper and mid esophagus. Inflammatory bowel disease The esophagus can be involved in Crohn disease. Aphthous ulcers are observed in the esophagus. Inflammatory strictures, sinus tracts, filiform polyps, and fistulas to adjacent structures may be observed. Histology shows diffuse and nodular lymphoid aggregates; 50% of EGD biopsy specimens show noncaseating granulomas. Metastatic cancer Diagnosis is best made by barium contrast radiography and CT scan. EGD is used to exclude primary esophageal cancer. Collagen vascular diseases Motility disorders of the esophagus lead to poor acid clearing, with resulting epithelial damage (ie, GERD in scleroderma). Medications (pill esophagitis) Antibiotics, potassium chloride, NSAIDs, quinidine, emperonium bromide, and Fosamax account for 90% of the reported cases. The following are important pill and patient factors:
- Chemical nature of drug
- Solubility
- Contact time with mucosa
- Size, shape, and pill coating
- Amount of water (ie, too little) taken to swallow pill (eg, Fosamax)
- Preexisting esophageal pathology (eg, stricture, achalasia)
EGD findings range from reddened edematous mucosa to small superficial ulcers to large ulcers with heaped up inflamed margins, often with exudate. Chemotherapy esophagitis Dactinomycin, bleomycin, cytarabine, daunorubicin, 5-fluorouracil, methotrexate, and vincristine may cause severe dysphagia because of oropharyngeal mucositis. Radiation and chemoradiation esophagitis Radiation therapy over 30 Gy to the mediastinum typically causes retrosternal burning and painful swallowing, which is usually mild and limited to the duration of therapy.
- A dose of 40 Gy causes mucosal redness and edema.
- A dose of 50 Gy causes a higher incidence and severity of esophageal damage.
- A dose of 60-70 Gy causes moderate-to-severe esophagitis with strictures, perforations, and fistulas.
Sclerosant and band ligation therapy for varices This can cause necrosis of esophageal tissues and mucosal ulcers. Incidence and severity are higher with sclerosant therapy. Later, strictures can develop.
Medical Care
Treatment is directed at the underlying cause. The goal of medical care is to treat the underlying cause and minimize morbidity. Treatment options are as follows:
- Candida esophagitis
- Topical nonabsorbable agents include nystatin, clotrimazole, and oral amphotericin B.
- Oral agents include fluconazole and itraconazole.
- Parenteral agents include amphotericin B, fluconazole, and flucytosine.
- Choice of agent depends on the severity of infection and degree of host defense impairment.
- HSV esophagitis diagnosis made at endoscopy
- Acyclovir
- Foscarnet for acyclovir-resistant cases
- Famciclovir (acyclovir analog)
- CMV esophagitis
- Ganciclovir (acyclovir analog)
- Foscarnet
- Varicella-zoster virus esophagitis
- Acyclovir
- Famciclovir
- Foscarnet for acyclovir-resistant cases
- EBV esophagitis: Acyclovir (may require long-term maintenance to suppress oral hairy leukoplakia)
- Human immunodeficiency virus esophagitis
- Corticosteroid therapy, usually for longer than 1 month
- Antiretroviral therapy for HIV
- Human papillomavirus esophagitis
- Often asymptomatic (No treatment is usually needed.)
- Systemic interferon-alfa, bleomycin, and etoposide used with variable results
- M tuberculosis esophagitis: Standard antituberculous therapy is used for immunocompetent hosts.
- Bacterial esophagitis: Normal flora, usually observed in immunocompromised patients, is extremely rare in healthy hosts.
- Infections are often polymicrobial and include Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus viridans, and Bacillus species.
- Broad-spectrum beta-lactam antibiotics are used, usually in combination with an aminoglycoside. Adjustments are based on response and culture results.
- Behçet disease esophagitis
- Corticosteroids for serious inflammation
- Chlorambucil or azathioprine for long-term therapy
- Graft versus host disease esophagitis
- Dilation and antireflux measures
- Prednisone, cyclosporine, azathioprine, and thalidomide
- Inflammatory bowel disease esophagitis
- Corticosteroid therapy for inflammatory lesions
- Dilation for strictures
- Surgery - May be needed for fistulas and strictures
- Metastatic cancer esophagitis
- Radiation therapy
- Palliation with stents
- Collagen vascular diseases esophagitis
- Medication-related esophagitis (pill esophagitis)
- Stop medication.
- Control of acid reflux may accelerate healing.
- Patients should take medication with plenty of water while sitting in the upright position.
- Chemotherapy esophagitis
- Radiation and chemoradiation esophagitis
Surgical Care
Surgical care may be necessary for perforation and fistulas.
Consultations
- Consult a gastroenterologist to facilitate diagnosis and treatment.
- Consulting an infectious disease specialist may be necessary in difficult cases.
- A surgical consultation may be necessary for perforation and fistulas.
- Other consultations may be sought, as indicated.
Diet
No particular restrictions are necessary. If the patient has odynophagia or is unable to consume calories orally, then gastric feeding or parenteral feeding may be needed.
Activity
No limitations on patient activity are necessary.
Therapy is directed at the underlying condition, with the goal of minimizing symptoms and preventing complications. The choice of the therapeutic agent depends on the severity of infection and the degree of host defense impairment. Medical therapy for fungal conditions falls into 3 categories, as follows: (1) topically active agents (eg, nystatin, clotrimazole, oral amphotericin B), (2) orally administered absorbable agents (eg, fluconazole, itraconazole), and (3) parenterally administered agents (eg, amphotericin B, fluconazole, flucytosine). Most patients with fungal esophagitis who are immunocompetent can be treated with a topical antifungal agent. They are virtually devoid of adverse effects and have few, if any, drug-drug interactions because they are not absorbed. The treatment of eosinophilic esophagitis continues to evolve. Various interventions, such as complete avoidance of precipitating food allergens, esophageal dilatation, corticosteroids, cromolyn sodium, and leukotriene inhibitors, have been performed. Until the natural history of this disease is understood more fully and appropriate trials are performed, the treatment of this condition will continue to be empirical.
Drug Category: Antifungal agents
Topical or systemic treatment of fungal infections.
| Drug Name | Clotrimazole (Mycelex) |
|---|
| Description | Nonabsorbable imidazole. Broad-spectrum synthetic antifungal agent that inhibits growth of yeasts by altering cell membrane permeability. |
|---|
| Adult Dose | Immunocompetent patients: 10 mg buccal troches dissolved 5 times/d for 1 wk
Immunocompromised patients: 100 mg vaginal tab dissolved in mouth tid |
|---|
| Pediatric Dose | <3 years: Not recommended
>3 years: Administer as in adults |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | None reported |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | Not for treatment of systemic fungal infections; avoid contact with the eyes; if irritation or sensitivity develops, discontinue use and institute appropriate therapy; abnormal findings on LFTs and SGOT have occurred; periodically monitor LFTs in hepatic disease |
|---|
| Drug Name | Nystatin (Mycostatin) |
|---|
| Description | Nonabsorbable polyene antifungal agent obtained from Streptomyces noursei. Binds to sterols in cell membrane of susceptible fungi, with resulting change in membrane permeability allowing leakage of intracellular components. Indicated for treatment of PO candidiasis. |
|---|
| Adult Dose | Troche: 200,000-400,000 U dissolved PO 4-5 times/d
Susp: 400,000-600,000 U swish and swallow 4-5 times/d for 1 wk |
|---|
| Pediatric Dose | Troche: Not established
Susp: Administer as in adults |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | None reported |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | Do not use to treat systemic mycoses; PO irritation or sensitization may occur; GI distress may occur with large doses |
|---|
| Drug Name | Fluconazole (Diflucan) |
|---|
| Description | Synthetic triazole fungistatic agent. Highly selective inhibitor of fungal cytochrome P-450 sterol C-14 alpha demethylation. |
|---|
| Adult Dose | 200 mg PO on day 1, then 100 mg PO qd for 2-3 wk after symptoms resolve
Alternatively, 400 mg PO on day 1, then 200 mg PO qd
Can use up to 400 mg/d |
|---|
| Pediatric Dose | 6 mg/kg PO on day 1, then 3 mg/kg PO qd for 3 wk; can use up to 12 mg/kg/d |
|---|
| Contraindications | Documented hypersensitivity; administration with terfenadine or cisapride |
|---|
| Interactions | Levels may increase with hydrochlorothiazide; fluconazole levels may decrease with long-term coadministration of rifampin; coadministration of fluconazole may decrease phenytoin concentrations; may increase concentrations of rifabutin, theophylline, tolbutamide, glyburide, and glipizide; effects of anticoagulants may increase with fluconazole coadministration; increases in cyclosporine and tacrolimus concentrations may occur when administered concurrently |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | Adjust dose for renal insufficiency; monitor closely if rashes develop and discontinue drug if lesions progress; may cause clinical hepatitis, cholestasis, and fulminant hepatic failure (including death) with underlying medical conditions such as AIDS or a malignancy while taking multiple concomitant medications; not recommended for nursing mothers; convenience and efficacy of single-dose regimen for treatment of vaginal yeast infections should be weighed against difficulties resulting from higher incidence of adverse reactions reported with PO fluconazole versus intravaginal agents; caution in patients taking OCPs containing ethinyl estradiol and levonorgestrel |
|---|
| Drug Name | Amphotericin B, conventional (Amphocil, Fungizone) |
|---|
| Description | Binds to sterols in the cell membrane and alters permeability. Used in patients with granulocytopenia. PO route infrequently used and has no advantage over PO clotrimazole or nystatin. |
|---|
| Adult Dose | 0.5 mg/kg/d IV in febrile patients or patients with disseminated disease for a total dose of 1.5-2 g over 6-12 wk
Alternatively, 0.3 mg/kg/d IV for 7-10 d |
|---|
| Pediatric Dose | Infants: Not established
Children: Administer as in adults |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Antineoplastic agents may enhance the potential of amphotericin B for renal toxicity, bronchospasm, and hypotension; corticosteroids, digitalis, and thiazides may potentiate hypokalemia; the risk of renal toxicity is increased with cyclosporine use |
|---|
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
|---|
| Precautions | Monitor renal function, serum electrolytes such as magnesium and potassium, liver function, CBC count, and hemoglobin concentrations; resume the therapy at the lowest level (eg, 0.25 mg/kg) when the therapy is interrupted for more than 7 d; hypoxemia, acute dyspnea, and interstitial infiltrates may occur in patients who are neutropenic receiving leukocyte transfusions (separate time of amphotericin infusion from time of leukocyte transfusion); fever and chills are not uncommon after first few administrations of drug; rare acute reactions may include hypotension, bronchospasm, arrhythmias, and shock |
|---|
| Drug Name | Anidulafungin (Eraxis) |
|---|
| Description | Antifungal agent of the echinocandin class. Inhibits synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls. Indicated to treat esophageal candidiasis, candidemia, and other forms of candidal infections (eg, intra-abdominal abscesses, peritonitis). |
|---|
| Adult Dose | Candidemia or other candidal infections: 200 mg IV on day 1, decrease dose on day 2 and thereafter to 100 mg/d IV
Esophageal candidiasis: 100 mg IV on day 1, decrease dose on day 2 and thereafter to 50 mg/d IV
Do not exceed infusion rate of 1.1 mg/min |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | None reported |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | Common adverse effects include hypokalemia, diarrhea, elevated hepatic enzyme levels, and headache; rare reports of serious hepatotoxicity; infusion-related reactions (eg, rash, urticaria, flushing, pruritus, dyspnea, hypotension) may occur, particularly with rapid infusion; following reconstitution, dilute further with D5W or NS before administration |
|---|
Drug Category: Antiviral agents
Treat HSV or CMV viral infections. In addition to the drugs listed below, famciclovir (Famvir), a prodrug of the antiviral agent penciclovir, which is not currently recommended for treatment, may replace acyclovir in prophylaxis and treatment.
| Drug Name | Acyclovir (Zovirax) |
|---|
| Description | Synthetic purine nucleoside analog that stops replication of viral DNA. Used for HSV esophagitis. |
|---|
| Adult Dose | 250 mg/m2 IV q8h for 7-10 d |
|---|
| Pediatric Dose | Administer as in adults |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Concomitant use of probenecid or zidovudine prolongs half-life and increases CNS toxicity of acyclovir |
|---|
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
|---|
| Precautions | Caution in renal failure or when using other nephrotoxic drugs |
|---|
| Drug Name | Foscarnet (Foscavir) |
|---|
| Description | Organic analog of inorganic pyrophosphate that inhibits replication of HSV and CMV. Used for acyclovir-resistant cases. |
|---|
| Adult Dose | Induction: 90 mg/kg IV q12h for 3-6 wk
Maintenance: 90-120 mg/kg/d IV single infusion |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Coadministration with potentially nephrotoxic drugs (eg, aminoglycosides, amphotericin B, IV pentamidine) may increase nephrotoxicity (do not administer unless potential benefits outweigh risks); coadministration with IV pentamidine may cause hypocalcemia |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | May cause decline in renal function; for correct dosing, obtain 24-h serum creatinine at baseline and continue to monitor (discontinue if serum creatinine <0.4 mL/min/kg); hydration may reduce nephrotoxicity; carefully monitor electrolytes (eg, calcium, magnesium); assess for electrolyte and mineral level abnormalities if mild perioral numbness, paresthesias symptoms, or seizures occur; granulocytopenia and anemia may occur (regularly monitor CBC count); infuse foscarnet solutions into veins with adequate blood flow to avoid local irritation; to avoid toxicity, do not administer by rapid or bolus IV injection |
|---|
| Drug Name | Ganciclovir (Cytovene) |
|---|
| Description | Acyclic nucleoside analog that inhibits replication of herpes viruses. Active against CMV and HSV. |
|---|
| Adult Dose | Induction: 5 mg/kg IV q12h for 2-3 wk
Maintenance: 6 mg/kg IV 5 times per wk |
|---|
| Pediatric Dose | Administer as in adults |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Concomitant administration with cytotoxic drugs such as dapsone, vinblastine, Adriamycin, pentamidine, flucytosine, vincristine, amphotericin B, trimethoprim/sulfamethoxazole combinations, or other nucleoside analogs may result in additive toxicity in bone marrow, spermatogonia, and the germinal layers of skin and GI mucosa (coadminister only if potential benefits outweigh risks); coadministration with imipenem-cilastatin may cause generalized seizures (use only if potential benefits outweigh risks); serum creatinine may increase following concurrent use of ganciclovir with either cyclosporine or amphotericin B; in the presence of probenecid, ganciclovir renal clearance is reduced; bioavailability may increase when didanosine is administered either 2 h prior to or simultaneously with ganciclovir; bioavailability of ganciclovir may decrease in the presence of zidovudine, while bioavailability of zidovudine is increased in the presence of ganciclovir |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | Clinical toxicity of ganciclovir includes granulocytopenia, anemia, and thrombocytopenia; because PO ganciclovir is associated with a higher rate of CMV retinitis progression compared to the IV formulation, use only when benefits outweigh risks (advanced HIV disease); half-life and plasma/serum concentrations of ganciclovir may be increased as a result of reduced renal clearance; dosages > 6 mg/kg IV may result in increased toxicity; rapid infusions may result in increased toxicity; initially, reconstituted solutions of IV ganciclovir have a high pH (11); phlebitis or pain may occur at site of IV infusion despite further dilution in IV fluids; administration of ganciclovir should be accompanied by adequate hydration; photosensitization (ie, photoallergy, phototoxicity) may occur |
|---|
Drug Category: Corticosteroids
Have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli.
| Drug Name | Prednisone (Deltasone, Sterapred, Orasone) |
|---|
| Description | Administered in immunosuppressive doses, which may vary based on the underlying disease process. Dose is usually slowly tapered over wk to mo. Equivalent dose of methylprednisolone (Solu-Medrol) may be used instead of prednisone. |
|---|
| Adult Dose | 30-60 mg PO qd or divided bid/qid; taper over few wk to mo, as symptoms resolve
Literature reports a large variability in dose; generally use lowest dose that produces a clinical response |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity; viral infection; peptic ulcer disease; hepatic dysfunction; connective tissue infections; fungal or tubercular skin infections; GI disease |
|---|
| Interactions | Coadministration with estrogens may decrease prednisone clearance; concurrent use with digoxin may cause digitalis toxicity secondary to hypokalemia; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics |
|---|
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
|---|
| Precautions | Abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur with glucocorticoid use; during stress (eg, surgery, illness) stress doses of short-acting steroids are necessary |
|---|
Further Inpatient Care
- The goals of treatment are disease-specific; however, relief of symptoms and maintenance of nutritional status are common outcomes. Goals of treatment are the same for inpatient and outpatient care.
In/Out Patient Meds
Complications
- Stricture formation, malnutrition, and, rarely, perforation or bleeding may occur.
Prognosis
- The prognosis is good with rapid diagnosis and proper treatment. Ultimately, prognosis depends on the underlying disease process.
Patient Education
Medical/Legal Pitfalls
- Fosamax in patients who are cirrhotic could precipitate GI bleeding from erosions over an esophageal varix.
- Always consider the possibility of systemic illness causing the esophageal manifestations (eg, AIDS, scleroderma, SLE, pemphigus).
Special Concerns
- Concerns are specific to the underlying disease process.
| Media file 1:
Esophagitis. Location of fungal and viral infections in ulcers. |
 |  View Full Size Image | |
Media type: Image
|
- Amaro R, Poniecka AW, Goldberg RI. Herpes esophagitis. Gastrointest Endosc. Jan 2000;51(1):68. [Medline].
- Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. Jan 2005;19(1):15-35. [Medline].
- Arora AS, Yamazaki K. Eosinophilic esophagitis: asthma of the esophagus?. Clin Gastroenterol Hepatol. Jul 2004;2(7):523-30. [Medline].
- AstraZeneca. Feldman's GastroAtlas Online. Available at: http://www.gastroatlas.com/login.aspx. [Full Text].
- Baehr PH, McDonald GB. Esophageal disorders caused by infection, systemic illness, medications, radiation, and trauma. In: Sleisenger & Fordtran Gastrointestinal and Liver Disease. 6th ed. Philadelphia, Pa: WB Saunders Co; 1998:519-539.
- Boyce HW. Medication induced esophagitis and caustic ingestion. In: AGA Spring Postgraduate Course. GI in the Next Century: Clinical Advances in Esophageal and Gastrointestinal Disorders. 1999.
- Bradley J, Movsas B. Radiation esophagitis: Predictive factors and preventive strategies. Semin Radiat Oncol. Oct 2004;14(4):280-6. [Medline].
- Cantù P, Velio P, Prada A, Penagini R. Ringed oesophagus and idiopathic eosinophilic oesophagitis in adults: an association in two cases. Dig Liver Dis. Feb 2005;37(2):129-34. [Medline].
- Catalano F, Terminella C, Grillo C, Biondi S, Zappalà M, Bentivegna C. Prevalence of oesophagitis in patients with persistent upper respiratory symptoms. J Laryngol Otol. Nov 2004;118(11):857-61. [Medline].
- Dieterich DT, Wilcox CM. Diagnosis and treatment of esophageal diseases associated with HIV infection. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. Nov 1996;91(11):2265-9. [Medline].
- Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;(2):CD003245. [Medline].
- Liacouras CA, Ruchelli E. Eosinophilic esophagitis. Curr Opin Pediatr. Oct 2004;16(5):560-6. [Medline].
- Lowe RC, Wolfe MM. The pharmacological management of gastroesophageal reflux disease. Minerva Gastroenterol Dietol. Sep 2004;50(3):227-37. [Medline].
- Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut. Jun 2005;54(6):746-51. [Medline].
- Mann NS, Leung JW. Pathogenesis of esophageal rings in eosinophilic esophagitis. Med Hypotheses. 2005;64(3):520-3. [Medline].
- McColl KE. Review article: Helicobacter pylori and gastro-oesophageal reflux disease--the European perspective. Aliment Pharmacol Ther. Dec 2004;20 Suppl 8:36-9. [Medline].
- Medical Economics Staff. Physicians' Desk Reference. 55th ed. Medical Economics Company: Montvale, NJ; 2001.
- Mimidis K, Papadopoulos V, Margaritis V, Thomopoulos K, Gatopoulou A, Nikolopoulou V, et al. Predisposing factors and clinical symptoms in HIV-negative patients with Candida oesophagitis: are they always present?. Int J Clin Pract. Feb 2005;59(2):210-3. [Medline].
- Noel RJ, Putnam PE, Collins MH, Assa'ad AH, Guajardo JR, Jameson SC, et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol. Jul 2004;2(7):568-75. [Medline].
- Patel AB, Edelman MJ, Kwok Y, Krasna MJ, Suntharalingam M. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. Nov 15 2004;60(4):1106-12. [Medline].
- Rath HC, Timmer A, Kunkel C, Endlicher E, Grossmann J, Hellerbrand C, et al. Comparison of interobserver agreement for different scoring systems for reflux esophagitis: Impact of level of experience. Gastrointest Endosc. Jul 2004;60(1):44-9. [Medline].
- Rodrigues F, Brandão N, Duque V, Ribeiro C, António AM. Herpes simplex virus esophagitis in immunocompetent children. J Pediatr Gastroenterol Nutr. Nov 2004;39(5):560-3. [Medline].
- Weigand K, Wagner-Thiessen E, Stolte M. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide. Z Gastroenterol. Oct 2004;42(10):1179-81. [Medline].
- Wilcox CM. Diagnosis and management of esophagitis in patients with AIDS. In: AGA Spring Postgraduate Course. GI in the Next Century: Clinical Advances in Esophageal and Gastrointestinal Disorders. 1999.
- Wilcox CM. Esophageal strictures complicating ulcerative esophagitis in patients with AIDS. Am J Gastroenterol. Feb 1999;94(2):339-43. [Medline].
- Wilcox CM. Esophagitis in the immunocompromised host. In: Castell DO, Richter JE, eds. The Esophagus. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:539-555.
- Winstead NS, Bulat R. Pill Esophagitis. Curr Treat Options Gastroenterol. Feb 2004;7(1):71-76. [Medline].
Esophagitis excerpt Article Last Updated: Jul 17, 2008
|
